Amendment to simplify import of drugs for testing
The Union Ministry of Health and Family Welfare (MoHFW) has drafted changes to the Drugs Rules, 1945 to make it easier for researchers and companies to bring small quantities of drugs into India for analytical and non‑clinical testing. The proposal introduces an acknowledgement‑based system that replaces the earlier licensing requirement for most such imports.
Key developments
- Applicants will submit a prior intimation form online and receive an electronic acknowledgement that permits import of the drug.
- The system applies to all drugs in small quantities except those in the categories of sex hormones, cytotoxic drugs, beta‑lactam drugs, biologics containing live microorganisms, and narcotic/psychotropic substances, which will still need a licence.
- The amendment mirrors a similar notification introduced earlier in 2026 for domestic test licences under the New Drugs and Clinical Trials Rules, 2019.
- Stakeholders can submit objections or suggestions to the Under Secretary (Drugs), MoHFW, or via email.
Important facts
The draft notification, dated 26 June 2026, is available on the official e‑gazette portal. The proposed change aims to cut the compliance burden, especially for start‑ups and research institutions that need rapid access to test materials. By removing the licence step, the import process becomes faster and more cost‑effective.
Relevance for UPSC
Understanding this amendment is important for several reasons:
- It reflects the government's focus on ease of doing business in the pharmaceutical sector, a recurring theme in GS III (Economy) and GS IV (Governance).
- The move supports the broader agenda of promoting research and innovation in India, aligning with the “Make in India” and “Atmanirbhar Bharat” initiatives.
- It showcases how regulatory reforms can stimulate the R&D sector, encouraging domestic drug development and reducing dependence on imports.
- For GS II (Polity), the amendment illustrates the role of the Ministry of Health in policy‑making and stakeholder consultation.
Way forward
After the public consultation period, the Ministry will incorporate feedback and issue a final Gazette Notification. Once enacted, importers will need to register on the online portal, submit the intimation, and retain the acknowledgement for customs clearance. The exemption will continue for the listed sensitive drug categories, ensuring that safety and control mechanisms remain intact.
Overall, the amendment is expected to accelerate drug research, lower entry barriers for new players, and strengthen India’s position as a hub for pharmaceutical innovation.